HARMONY ALLIANCE

6th General Assembly

18 & 19 November 2021
The Hague, the Netherlands
IN PERSON & VIRTUAL

HANDOUT

www.harmony-alliance.eu
www.bigdataforbloodcancer.eu

innovative medicines initiative

efpia

HARMONY
ALLIANCE
imi
innovative medicines initiative
efpia
#bigdataforbloodcancer
Accelerating research to increase treatment efficacy, decrease adverse effects, prolong survival, and ultimately contribute to **patients' quality of life**.

HARMONY ALLIANCE

HARMONY

53 Partners, Patient Cluster of 7 European Patient Organizations, 43 Associated Members.

Budget: Euro 40 million.

Period: January 2017 until December 2021.

HARMONY PLUS

39 Partners, 8 Associated Partners.

Budget: Euro 11,8 million.

Period: October 2020 until September 2023.

Uniting the European hematology community



EUROPEAN HEMATOLOGY ASSOCIATION
30 YEARS OF EXCELLENCE
IN PATIENT CARE, RESEARCH, AND EDUCATION IN HEMATOLOGY
We connect, support, harmonize and advocate for professionals in hematology.
EHA Campus
Research
European Projects
EHA Annual Congress and Meetings

EUROPEAN HEMATOLOGY ASSOCIATION

"The European Hematology Association, EHA, welcomes HARMONY Partners, the HARMONY Patient Cluster, HARMONY Associated Members, HARMONY PLUS Partners, HARMONY PLUS Associated Partners, as well as close external relations at the HARMONY Alliance General Assembly 2021. We are proud to be the host for the 6th HARMONY and for the 2nd HARMONY PLUS annual meetings. We wish you an informative, inspiring and interactive event."

HARMONY ALLIANCE

Content handout

1. Program in detail
2. Overview Participants
3. #BigDataForBloodCancer
4. Community

#bigdataforbloodcancer

Sharing anonymized data in a secure way, for research purposes, **is like a new form of blood donation** in the era of digitalization and Big Data.
... in result, it has the power ot save human lives...

1

Program in detail

Thursday, 18 November 2021

09:00-10:30 HARMONY Alliance Ethics Advisory Board/WP8 Meeting

12:00-13:00 Venue meeting rooms open | The Hague Conference Centre – 1st floor

Start day 1 of the HARMONY Alliance General Assembly
Registration and walking Lunch at the HARMONY Plaza

13:00-13:20 **Words of welcome**

Frank Schulz
Interim Managing Director
European Hematology Association

Elizabeth Macintyre
President
European Hematology Association

13:20-14:20 **Keynote presentations**

Future perspective of the European Medicines Agency on the HARMONY Big Data Platform

Francesco Pignatti
Head of Oncology and Haematology
European Medicines Agency (EMA)
(attending virtual)

New Therapeutic Strategies in AML: The Circuitous Route in Drug Development

Martin S. Tallman
President
American Hematology Society
(attending remotely)

14:20-15:00 **Presentations, discussion and interaction**
HARMONY Big Data Platform, the HARMONY Data barometer and the HARMONY Data lake: A detailed update and outlook

Call to action: How to improve quality of the data; what kind of data is needed in the future; datasets with PROs and QoL; Definition of data priorities and purpose; RWD / RCT data; Place of RWE in future collaboration.

Jesús María Hernández
HARMONY Coordinator
IBSAL

Guillermo Sanz
HARMONY Co-Chair
Hospital Universitario La Fe
(attending remotely)

Thursday, 18 November 2021

15:00-15:15 Short break at the HARMONY Plaza

15:15 – 15:55 **Keynote presentations**

Keeping up with the speed of research in hematology! Can real-world data help?

Farzad Ali
Pfizer
(attending remotely)

Patient involvement in blood cancer research now and in the future

Tamas Bereczky
Leukanet
HARMONY Patient Cluster
(attending remotely)

16:00-17:30 **Results in AML, MM, CLL, ALL**

Lars Bullinger
Charité Universitätsmedizin Berlin
AML

Mattia D'Agostino
University of Turin
MM

Thomas Chatzikonstantinou
G. Papanicolaou Hospital
CLL

Anthony Moorman
University of Newcastle
ALL
(attending remotely)

17:20-17:30 **Interaction and closing**

Input Communication, Dissemination and Stakeholder engagement

Ellen de Waal
HARMONY Alliance Communications
European Hematology Association

Wrap-up day 1

Jesús María Hernández
HARMONY Coordinator
IBSAL

17:30 **End of day 1**

17:30-21:00 **Social activities for attendees present in person**

Friday, 19 November 2021

08:30 - Venue meeting rooms open | The Hague Conference Centre – 1st floor

Day 2 of the HARMONY Alliance General Assembly

09:00- 10:30 **Updates in CML, MPN, MDS and NHL**

Andreas Hochhaus
University of Jena
CML
(attending remotely)

Tiziano Barbui
Fondazione per la Ricerca Ospedale di Bergamo
MPN
(attending remotely)

Andrea Kündgen
Heinrich Heine University Düsseldorf
MDS

Thomas Weber ,
Universitätsklinikum Halle
NHL
(attending remotely)

10:30-11:30 **HARMONY Core Outcome Sets about Delphi surveys, last round and outlook**

Lars Bullinger
Charité Universitätsmedizin Berlin

Katharina Lang
Charité Universitätsmedizin Berlin

Renate Schulze-Rath
Bayer

Martje Barbus
AbbVie
(attending remotely)

11:30-12:30 **Keynote presentation**

Perspective of EBMT on embedding the use of HARMONY

Anna Sureda
President-Elect
EBMT
European Society for Blood and Marrow Transplantation

Common challenges, lessons learned and outlook by IMI Project: EHDEN

Nigel Hughes
Project Lead
EHDEN
European Health Data & Evidence Network
(attending remotely)

Friday, 19 November 2021

12:45-13:00 Lunch at the HARMONY Plaza

13:00-13:40 **HARMONY Alliance General Assembly official topics**

HARMONY 3rd and 4th Amendment

Santiago Moralejo del Arco
IBSAL

HARMONY PLUS RP1

Cristina Abad Rodríguez
Hospital Universitario La Fe

Montse Camprubi
Synapse
(attending remotely)

13:40-14:00 **HARMONY & HARMONY PLUS Outlook | Closing remarks**

14:00 **End of day 2**

HARMONY
ALLIANCE
HARMONY
BIG DATA
PLATFORM
DATA
PROCESSING

2

Overview Participants

Overview participants | by order of last name

Cristina	**Abad Rodríguez**	Medical Research Institute La Fe	MDS	WP1 - Project management
María	**Abáigar**	IBSAL - Cancer Research Center	AML	WP1 - Project management
Farzad	**Ali**	Pfizer	MM	WP6 - Payers/Providers/HTA/EMA
Jenny	**Amaya**	Amgen	ALL	WP1 - Project management
Esther	**Anguiano Batanero**	IBSAL-GMV	ALL	WP3&4 - Data Access and Data Platform
Teresa	**Arquero**	Fundación Jimenez Diaz	MDS	WP3&4 - Data Access and Data Platform
Lourdes	**Baeza**	Takeda	ALL	WP2 - Definition of outcomes
Tiziano	**Barbui**	Fondazione Ricerca Ospedale Bergamo	MPN	WP1 - Project management
Martje	**Barbus**	AbbVie Germany	AML	WP2 - Definition of outcomes
Iris	**Bargalló**	EBMT	Other	WP8 - Legal, Ethics, and Governance
Axel	**Benner**	DKFZ	AML	WP5 - Data analytics
Tamas	**Bereczky**	Leukanet	Other	WP6 - Payers/Providers/HTA/EMA
Marilena	**Bicchieri**	Humanitas Hospital - Milan	AML	WP6 - Payers/Providers/HTA/EMA

Nathalie	**Bouxin**	Pfizer	MM	WP3&4 - Data Access and Data Platform
Susan	**Branford**	SA Pathology	CML	WP5 - Data analytics
Lars	**Bullinger**	Charité University Medicine Berlin	AML	WP2 - Definition of outcomes
Alba	**Burillo Navarro**	IBSAL	Pediatric HMs	WP3&4 - Data Access and Data Platform
Alba	**Burillo Navarro**	IBSAL	Pediatric HMs	WP3&4 - Data Access and Data Platform
Elena	**Cabezudo**	Moises Broggi (ICO_Hospitalet)	MM	WP3&4 - Data Access and Data Platform
Maria Jose	**Calasanz Abinzano**	University of Navarra	AML	WP2 - Definition of outcomes
Montse	**Camprubi**	Synapse Research Management Partners	Other	WP1 - Project management
Alessandra	**Carobbio**	FROM Research Foundation Bergamo Hospital	MPN	WP5 - Data analytics
Alessandra	**Carobbio**	FROM Research Foundation Bergamo Hospital	MPN	WP5 - Data analytics
Sandra	**Castaño Díez**	Hospital Clínic Barcelona	AML	WP7 - Dissemination, Communication, and Training
Gastone	**Castellani**	Bologna University	AML	WP5 - Data analytics
Edmond	**Chan**	Janssen	MM	WP7 - Dissemination, Communication, and Training
Thomas	**Chatzikonstantinou**	G. Papanicolaou Hospital	CLL	WP1 - Project management
Vasyl	**Chekhun**	RE Kavetsky Inst. of Experimental Pathology, Oncology and Radiobiology	ALL	WP1 - Project management

Solène	**Clavreul**	Myeloma Patients Europe	MM	WP6 - Payers/Providers/HTA/EMA
Jacqueline	**Cloos**	Amsterdam UMC	AML	WP2 - Definition of outcomes
Jan	**Cornelissen**	Erasmus MC	CML	WP3&4 - Data Access and Data Platform
Marta	**Crespo**	VHIO	CLL	WP2 - Definition of outcomes
Mattia	**D' Agostino**	University of Turin	MM	WP2 - Definition of outcomes
Dalia	**Dawoud**	NICE	Other	WP6 - Payers/Providers/HTA/EMA
Eleonora	**De Bellis**	GIMEMA	APL	WP2 - Definition of outcomes
Ellen	**de Waal**	European Hematology Association	AML	WP7 - Dissemination, Communication, and Training
Mónica	**del Rey**	IBSAL	MDS	WP1 - Project management
Elena	**del Rey**	Synapse Research Management Partners	Other	WP1 - Project management
Matteo	**Della Porta**	Humanitas Hospital - Milan	MDS	WP6 - Payers/Providers/HTA/EMA
María	**Díez Campelo**	University Hospital of Salamanca	MDS	WP5 - Data analytics
Konstanze	**Döhner**	University Hospital of Ulm	AML	WP2 - Definition of outcomes
Michael	**Doubek**	University Hospital Brno	CLL	WP5 - Data analytics
Jacqueline	**Dubow**	VCM	MDS	WP6 - Payers/Providers/HTA/EMA

Javier	**Elicegui**	IBSAL	AML	WP5 - Data analytics
Thomas	**Engsig**	Aarhus Universitetshospital AUK	NHL	WP2 - Definition of outcomes
Blanca	**Espinet**	Hospital Del Mar Barcelona	CLL	WP5 - Data analytics
Nicola	**Evans**	International CML Foundation	CML	WP3&4 - Data Access and Data Platform
Neus	**Fabregat**	Hospital Universitario La Fe	MDS	WP1 - Project management
Piero	**Fantacci**	Menarini	AML	WP1 - Project management
Pierre	**Fenaux**	EuroBloodNet	MDS	WP3&4 - Data Access and Data Platform
Ainhoa	**Fernández**	Sespa	AML	WP2 - Definition of outcomes
Miguel	**Ferreiro**	GMV	Other	WP3&4 - Data Access and Data Platform
Sara	**Galimberti**	University of Pisa	CML	WP1 - Project management
James	**Gallagher**	Pfizer	MM	WP6 - Payers/Providers/HTA/EMA
Jan	**Geissler**	Leukanet | HARMONY Patient Cluster	Other	WP6 - Payers/Providers/HTA/EMA
Eulalia	**Genesca**	Josep Carreras Institute	ALL	WP5 - Data analytics
Sergey	**Gerasymchuk**	RE Kavetsky Inst. of Experimental Pathology, Oncology and Radiobiology	ALL	WP1 - Project management
Paolo	**Ghia**	European Research Intiative on CLL - ERIC	CLL	WP2 - Definition of outcomes

Enrico	**Giampieri**	University of Bologna	MDS	WP5 - Data analytics
Teresa	**González**	IBSAL	AML	WP5 - Data analytics
Luca	**Guarnera**	University of Rome Tor Vergata	APL	WP3&4 - Data Access and Data Platform
Yann	**Guillevic**	B.M.S.	MM	WP6 - Payers/Providers/HTA/EMA
Miriam	**Gutierrez Serrano**	Ursalud	Other	WP5 - Data analytics
Anna	**Halstead**	Newcastle University	ALL	WP2 - Definition of outcomes
Katy	**Harrison**	NICE	AML	WP6 - Payers/Providers/HTA/EMA
Caroline	**Heckman**	University of Helsinki	AML	WP5 - Data analytics
Rüdiger	**Hehlmann**	ELN Foundation	AML	WP3&4 - Data Access and Data Platform
Florian	**Heidel**	Internal Medicine C, University Medicine Greifswald	MPN	WP1 - Project management
Ana	**Hernández Blázquez**	IBSAL	ALL	WP1 - Project management
Jesús María	**Hernández Rivas**	IBSAL	ALL	WP1 - Project management
Andreas	**Hochhaus**	University Clinic Jena	CML	WP2 - Definition of outcomes
Nigel	**Hughes**	EHDEN, European Health Data & Evidence Network	EHDEN	EHDEN
Brian	**Huntly**	University of Cambridge	AML	WP2 - Definition of outcomes

Mariam	**Ibáñez**	IIS LA FE	CLL	WP1 - Project management
Sofia	**Iqbal**	Janssen	ALL	WP6 - Payers/Providers/HTA/EMA
Niels	**Jensen**	MDS Patient Support	MDS	WP7 - Dissemination, Communication, and Training
Oussama	**Karroum**	IMI, Innovative Medicines Initiative	IMI	WP1 - Project management
Charikleia	**Kelaidi**	Aghia Sophia Children's Hospital	Pediatric HMs	WP2 - Definition of outcomes
Anne Sophie	**Kubasch**	University Hospital Leipzig	MDS	WP3&4 - Data Access and Data Platform
Andrea	**Kündgen**	Heinrich-Heine University Duesseldorf	MDS	WP2 - Definition of outcomes
Edoardo	**la Sala**	Fondazione GIMEMA - Franco Mandelli onlus	AML	WP5 - Data analytics
Alan	**Lamb**	NICE	MM	WP6 - Payers/Providers/HTA/EMA
Katharina	**Lang**	Charité University Medicine Berlin	Other	WP2 - Definition of outcomes
Peter	**Loffelhardt**	MPN España	MPN	WP1 - Project management
Bob	**Löwenberg**	Erasmus MC	AML	WP2 - Definition of outcomes
Elizabeth	**Macintyre**	Hôpital Necker-Enfants Malades et Université European Hematology Association	Other	WP7 - Dissemination, Communication, and Training
Barbara	**Martelli**	INFN-CNAF	Other	WP3&4 - Data Access and Data Platform
Cristna	**Martinez Ruiz**	AEMPS	Other	WP6 - Payers/Providers/HTA/EMA

Jiri	**Mayer**	University Hospital Brno	ALL	WP3&4 - Data Access and Data Platform
Konstantinos	**Mefsout**	AbbVie	Other	WP6 - Payers/Providers/HTA/EMA
Klaus	**Metzeler**	University of Leipzig	AML	WP3&4 - Data Access and Data Platform
Silvia	**Montoto**	St Bartholomew's hospital	NHL	WP2 - Definition of outcomes
Anthony	**Moorman**	Newcastle University	Pediatric HMs	WP2 - Definition of outcomes
Santiago	**Moralejo**	IBSAL	AML	WP1 - Project management
Mireya	**Morote Faubel**	Hospital Universitario y Politécnico La Fe	AML	WP1 - Project management
Vitaliy	**Mykytiv**	Cork University Hospital	AML	WP3&4 - Data Access and Data Platform
Gabriele	**Nagel**	Ulm University	AML	WP3&4 - Data Access and Data Platform
Anastasia	**Naoum**	European Hematology Association	CML	WP6 - Payers/Providers/HTA/EMA
Samantha	**Nier**	Acute Leukemia Advocates Network	ALL	WP7 - Dissemination, Communication, and Training
Maria	**Orea**	EBMT	MDS	WP1 - Project management
Juan Carlos	**Ortiz**	IBSAL	AML	WP1 - Project management
Gert	**Ossenkoppele**	Amsterdam UMC	AML	WP2 - Definition of outcomes
Laura	**Palomo**	VHIO	MDS	WP3&4 - Data Access and Data Platform

Francesca	**Paoloni**	Fondazione GIMEMA	ALL	WP3&4 - Data Access and Data Platform
Antonio	**Pérez**	GMV	Other	WP3&4 - Data Access and Data Platform
Inmaculada	**Pérez Garro**	GMV	Other	WP3&4 - Data Access and Data Platform
Francesco	**Pignatti**	EMA	EMA	EMA
Kimmo	**Porkka**	Helsinki University Hospital Cancer Center	AML	WP5 - Data analytics
Sarka	**Pospisilova**	Masaryk University and University Hospital Brno	CLL	WP2 - Definition of outcomes
Felipe	**Prosper**	Clinica Universidad de Navarra	MDS	WP2 - Definition of outcomes
Tatjana	**Pyatchanina**	RE Kavetsky Inst. of Experimental Pathology, Oncology and Radiobiology	ALL	WP1 - Project management
Dirk	**Reinhardt**	GPOH	Pediatric HMs	WP2 - Definition of outcomes
Josep-Maria	**Ribera**	ICO-Hospital Germans Trias i Pujol	ALL	WP3&4 - Data Access and Data Platform
Jordi	**Ribera**	Josep Carreras Leukaemia Research Institute	ALL	WP2 - Definition of outcomes
Ana E.	**Rodríguez**	IBSAL	CLL	WP6 - Payers/Providers/HTA/EMA
Olga	**Rossylna**	RE Kavetsky Inst. of Experimental Pathology, Oncology and Radiobiology, Nati	ALL	WP1 - Project management
Maral	**Saadati**	Saadati Solutions	AML	WP5 - Data analytics
Elena	**Sánchez**	IBSAL	AML	WP3&4 - Data Access and Data Platform

Guillermo	**Sanz Santillana**	Hospital Universitario La Fe	MDS	WP1 - Project management
Simona	**Scartoni**	Menarini Ricerche	AML	WP5 - Data analytics
Frank	**Schulz**	European Hematology Association	Other	WP7 - Dissemination, Communication, and Training
Renate	**Schulze-Rath**	Bayer AG	AML	WP2 - Definition of outcomes
Aoife	**Smyth**	Novartis Pharmaceuticals	MPN	WP5 - Data analytics
Francesc	**Sole**	Institut Josep Carreras	MDS	WP3&4 - Data Access and Data Platform
Pieter	**Sonneveld**	Erasmus MC	MM	WP1 - Project management
Tomasz	**Stokłosa**	Medical University of Warsaw	CML	WP2 - Definition of outcomes
Eric	**Sträng**	Charité University Medicine Berlin	AML	WP5 - Data analytics
Ana Maria	**Sureda**	Instituto Catalan de Oncologia-Hospitalet | EBMT	NHL	WP3&4 - Data Access and Data Platform
Martin	**Tallman**	Memorial Sloan Kettering Cancer Center.	AML	WP2 - Definition of outcomes
Jesse	**Tettero**	Amsterdam UMC	AML	WP2 - Definition of outcomes
Ian	**Thomas**	Cardiff University	AML	WP3&4 - Data Access and Data Platform
Giulia	**Tonini**	Menarini Ricerche	AML	WP5 - Data analytics

Laura	**Tur**	**GMV**	Other	WP3&4 - Data Access and Data Platform
Peter	**Valk**	**Erasmus MC**	AML	WP5 - Data analytics
Linda	**van den Berg**	**European Hematology Association** | Medical Writing HARMONY (Washoe)	Other	WP7 - Dissemination, Communication, and Training
Alberto	**Vasconcelos**	**Bristol Myers Squibb**	AML	WP2 - Definition of outcomes
Elvira	**Velloso**	**Faculdade de Medicina da universidade de Sao Paulo**	MDS	WP1 - Project management
Adriano	**Venditti**	**Tor Vergata University**	AML	WP1 - Project management
Jurjen	**Versluis**	**Erasmus MC**	AML	WP2 - Definition of outcomes
Belén	**Vidriales**	**University Hospital of Salamanca**	AML	WP8 - Legal, Ethics, and Governance
Ángela	**Villaverde Ramiro**	**IBSAL**	AML	WP5 - Data analytics
Rubén	**Villoria**	**GMV**	Other	WP3&4 - Data Access and Data Platform
Maria Teresa	**Voso**	**Tor Vergata University**	APL	WP2 - Definition of outcomes
Jan	**Walewski**	**Maria Sklodowska-Curie National Research Institute of Oncology**	NHL	WP3&4 - Data Access and Data Platform
Thomas	**Weber**	**UK-Halle Klinik für Innere Medizin IV**	NHL	WP6 - Payers/Providers/HTA/EMA
Jennifer	**Webster**	**Pfizer**	AML	WP3&4 - Data Access and Data Platform

Sally	**Wetten**	**Amgen**	MM	WP2 - Definition of outcomes
Sophie	**Wintrich**	**MDS UK**	MDS	WP6 - Payers/Providers/HTA/EMA
William	**Wood**	**University of North Carolina**	ASH	MM
Gabriela	**Yumi**	**AEMPS**	Other	WP6 - Payers/Providers/HTA/EMA

This overview is update per 16 November 2020.

3

#bigdataforbloodcancer

On behalf of the HARMONY Alliance Communications Team we thank you very much for your input and support to create content that will generate interest and impact.

Find below and in the next pages an impression of the #BigDataforBloodCancer Awareness Campaign.

www.bigdataforbloodcancer.eu

www.harmony-alliance.eu

#bigdataforbloodcancer: Powered by the HARMONY Alliance.

The HARMONY Alliance is using Big Data to develop more personalized treatments for blood cancer patients. This is a team effort involving hospitals, academic institutions, pharmaceutical companies, regulatory agencies, and patient organizations.

In June 2021 the #BigDataForBloodCancer Awareness Campaign was launched in June 2021 targeted at Clinicians and Researchers >

In our Fall 2021 #BigDataForBloodCancer Awareness Campaign, during the Bloodcancer Awareness Month, we engaged with a broad audience to explain what Big Data can mean for the lives of patients and for the daily work of doctors in the clinic >
In addition, we launched the 1st World Big Data for Blood Cancer Day on 30 September 2021.

An impression:



HARMONY ALLIANCE

BIG DATA FOR BLOOD CANCER

"The survival for pediatric Acute Lymphoblastic Leukemia (ALL) is fantastic. It is now mainly about better survival. Children with blood cancer still have their lives ahead of them. The research projects that HARMONY is conducting will have a valuable impact on children, teenagers and young adults with cancer".

Anita Kienesberger
CCI Europe
HARMONY Patient Cluster

BIG DATA FOR BLOOD CANCER

"We want to know which genes are associated with poor outcomes. This knowledge may allow clinicians to give patients a more reliable estimate of what they can expect in terms of the clinical course of the disease. In addition, it may affect treatment choices".

Richard Rosenquist
Karolinksa Instutet
HARMONY Partner

BIG DATA FOR BLOOD CANCER

"By collecting data from thousands of patients with Chronic Lymphocytic Leukemia (CLL), we could create substantial groups of patients with the same genetic aberration, and study the clinical outcome, response to therapy, and life expectancy of these patients. This may allow clinicians to tailor the treatment to the patient's unique characteristics".

Paolo Ghia, European Research Initiative on CLL (ERIC), HARMONY Lead Chronic Lymphocytic Leukemia

BIG DATA FOR BLOOD CANCER

"We think that a less intensive treatment will suffice in a substantial number of pediatric patients with Acute Lymphoblastic Leukemia (ALL). Key challenge is to develop more robust prognostic markers to identify these patients. With its unique Big Data Platform, HARMONY offers excellent opportunities to tackle this challenge".

Anthony Moorman
Newcastle University, HARMONY Lead Acute lymphoblastic leukemia

BIG DATA FOR BLOOD CANCER

"Using data from many with multiple myeloma (MM), we discovered that patients who are currently considered as 'intermediate-risk patients' constitute a quite diverse group with varying risk of progression or death. Oncologists can use our improved risk stratification model to make a more precise prognosis and select the best treatment for patients with MM".

Mattia D'Agostino
University of Turin
HARMONY Lead Multiple Myeloma

BIG DATA FOR BLOOD CANCER

"HARMONY teams have identified more than 80,000 anonymized data sets of patients with Hematological Malignancies, and also developed state-of-the art Big Data analytics solutions to mine these data. Data analysis becomes more challenging now that the data is larger and more complex".

Kimmo Porkka
University of Helsinki
HARMONY Partner



HARMONY ALLIANCE

During BloodCancer Awareness Month, September 2021, we supported:

- 1 September: World CLL Day
- 4 September: World Leukemia Day
- 9 September: MPN Awareness Day
- 15 September: World Lymphoma Awareness Day
- 22 September: World CML Day
- 24 September: World Cancer Research Day









Relevant links to scan regularly:

The HARMONY Alliance Community Forum,
our internal communication tool > | https://internal.harmony-alliance.eu/



Our news page at the HARMONY Alliance website >
Stay tuned for more blogs and press releases. | https://www.harmony-alliance.eu/en/news



Our meetings page at the HARMONY Alliance website > | https://www.harmony-alliance.eu/en/meet-us



4
Community

HARMONY

The first and largest Public-Private Partnership in **Hematology**

Focus on **Big Data** in

- **ALL** – Acute Lymphoblastic Leukemia
- **AML** – Acute Myeloid Leukemia
- **Childhood HMs** – Childhood Hematologic Malignancies
- **CLL** – Chronic Lymphocytic Leukemia
- **MM** – Multiple Myeloma
- **NHL** – Non-Hodgkin Lymphoma
- **MDS** – Myelodysplastic Syndromes

Budget **40 million Euro**

5 year project

From January 2017 until December 2021

Community of multi-stakeholder organizations representing **18 European countries**

39 partners

Patient Cluster with **9 European** Patient Organizations

43 Associated Members

www.harmony-alliance.eu | #bigdataforbloodcancer

Funded by: imi, efpia

HARMONY PLUS

Part of the largest Public-Private Partnership in **Hematology**

Focus on **Big Data** in

- **MPN** – Myeloproliferative Disorders
- **CML** – Chronic Myeloid Leukemia
- **PV** – Polycythaemia Vera
- **ET** – Essential Thrombocythemia
- **Myelo-fibrosis** – Myelofibrosis
- **HL** – Hodgkin's Lymphoma
- **WM** – Waldenström Macroglobulinaemia
- and other rare blood cancers

Budget **11,8 million Euro**

6,7 IMI Funding, 5,1 EFPIA In-kind

3 year project

From January 2017 until December 2021

Community of

39 partners

8 associated partners

www.harmony-alliance.eu | #bigdataforbloodcancer

Funded by: imi, efpia

The HARMONY Alliance community consists of experts working at HARMONY Partners, HARMONY Patient Cluster Organizations, HARMONY Associated Members, HARMONY PLUS Partners, HARMONY PLUS Associated Partners. Together we are representing 18 European Countries.

Thank you very much for your contributions so far!

HARMONY

Partners

Abbvie, Agencia Española de Medicamentos y Productos Sanitarios/AEMPS, Amgen Assistence Publique- Hopitaux de Paris/AP-HP, Barts Health NHS Trust, Bayer, BFArM/Bundesinstitut für Arzneimittel und Medizinprodukte, Celgene-BMS, Charité – Universitätsmedizin Berlin, EAPM, European Alliance for Personalised Medicine, ELN Foundation, EORTC/European Org. for Research and Treatment of Cancer, Erasmus MC, ERIC European Research Initiative on CLL, European Group for Blood and Marrow Transplantation/EBMT, European Hematologic Asscotiation/EHA, FisMonlus Fondazione Italiana Sindromi, Flanders Institute of Biotechnology/VIB, Genome Research Limited, German Society of Pediatric Onco-hema/GPOH, GMV, Goethe University Frankfurt, GRAALL/Group for Research on Adult ALL, Groupe Francophone des Myelodysplasies/GFM, Heinrich-Heine-Universitaet-Dusseldorf, Hospital Universitario La Fe de la Comunidad Valenciana, IBSAL, IJC Josep Carreras Leukaemia Research Institute, Janssen, LeukaNET Patient Advocacy Group, LMU Ludwig Maximilians Universität München, Masarykova Univerzita, MediSapiens, Menarini Ricerche, Munich Leukemina Laboratory GmbH/MLL, NICE/The National Institute for Health and Care Excellence, Novartis, OPBG, Pfizer, Synapse Research Management Partners, Takeda, The Lymphoma Scientific Association/LYSA, Universitätsmedizin Halle, UNIBO Alma Mater Studiorum - Università di Bologna, Universita degli studi di Torino, Universidad de Navarra, Universitaet Ulm, University Hospital Vall d'Hebron, University of Cambridge, University of Helsinki, University of Newcastle upon Tyne, University of Rome Tor Vergata, University of York, VU University Medical Center.

Patient Cluster

Acute Leukemia Advocates Network, Child Cancer International Europe, CLL Advocates Network, *CML Advocates Network*, Lymphoma Coalition, MDS Alliance, *MPN Advocates Network*, Myeloma Patients Europe.

Associated Members

Aghia Sophia Hospital, ALFA Group, AML-CG, Austrian Group Medical Tumour Therapy, Azienda Ospedaliero Universitaria di Ferrara, Cardiff University - UK NCRI, Carol Davila University of Medicine and Pharmacy, CHU Nice, CZECH Leukemia Study Group-FOR LIFE, European Myeloma Network, Faculty Carl Gustav Carus - Technical University of Dresden, FICUS, Fondazione GIMEMA, Fondazione IRCCS Ca´Granda Ospedale Magglore Policlinico, Fondazione per la Ricerca Ospedale di Bergamo, GELTAMO/Grupo Español de linfomas y transplantes de médula ósea, GENYO, GESMD, Grupo Español de Síndromes Mielodisplásticos, Grupo Latinoamericano de SMD/GLAM, Hospital 12 de Octubre, Hospital del Mar, HOVON, HUMANITAS, INAB/CERTH, Institute of Applies Biosciences at the Center for Research and Technology Hellas, Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori/IRST, IRCCS, Israeli Society of Hematology and Blood Transfusion, Karolinska Institute, Kavetsky Institute, Medical University of Lublin, Medical University of Wroclaw, National University of Ireland - Blood Cancer Network, Oncotyrol - Center for Personalized Cancer Medicine, Ospedale Vita-Salute San Raffaele, PALG, PETHEMA, Queen University Belfast, Rigshospitalet, Royal Bournemouth, Spanish CETLAM Cooperative Group, The Fondazione Italiana Linfomi ONLUS, Universita de Firenze, Universitá degli studi de Bari Aldo Moro, Universität Leipzig, Universitätsklinikum Essen, Universitätsklinikum Hamburg Eppendorf, University of Eastern Piedmont and Oncology Institute Southern Switzerland, University of Milano-Bicocca, University of Pisa, University of Southampton.

Partners

Agencia Española de Medicamentos y Productos Sanitarios/AEMPS, Bayer, BFArM/ Bundesinstitut für Arzneimittel und Medizinprodukte, Celgene-BMS, Charité – Universitätsmedizin Berlin, ELN Foundation, Erasmus MC, ERIC European Research Initiative on CLL, EBMT/European Group for Blood and Marrow Transplantation, European Hematology Association/EHA, FisMonlus Fondazione Italiana Sindromi, Flanders Institute of Biotecnology/VIB, Genome Research Limited, German Society of Pediatric Onco-hema/GPOH, GMV, Groupe Francophone des Myelodysplasies/GFM, Heinrich-Heine-Universität-Dusseldorf, Hospital Universitario La Fe de la Comunidad Valenciana, IBSAL, IJC Josep Carreras Leukaemia Research Institute, Janssen, LeukaNET Patient Advocacy Group, LMU Ludwig Maximilians Universität Munchen, Masarykova Univerzita, MediSapiens, Menarini Ricerche, Munich Leukemina Laboratory GmbH/MLL, NICE/The National Institute for Health and Care Excellence, Novartis, OPBG, Pfizer, Synapse Research Management Partners, The Lymphoma Scientific Association/LYSA, Universitätsmedizin Halle, Universidad de Navarra, UNIBO - INFN-CNAF, UNIBO Alma Mater Studiorum - Università di Bologna, Universita degli studi di Torino, Universität Ulm, University of Cambridge, University of Helsinki, University of Newcastle upon Tyne, University of York, VU University Medical Center.

Patient Cluster

Acute Leukemia Advocates Network, Child Cancer International Europe, CLL Advocates Network, CML Advocates Network, *Lymphoma Coalition, MDS Alliance*, MPN Advocates Network, *Myeloma Patients Europe.*

Associated Partners

Assistence Publique- Hopitaux de Paris/AP-HP, EAPM/European Alliance for Personalised Medicine, EORTC/European Org. for Research and Treatment of Cancer, Goethe University Frankfurt, GRAALL Group for Research on Adult ALL, University Hospital Vall d'Hebron University of Rome Tor Vergata.

Contact

HARMONY Coordination Office
Institute of Biomedical Research
of Salamanca (IBSAL)
Salamanca, Spain

harmonyoffice@ibsal.es
+34 678 841 121

HARMONY Communications
European Hematology Association (EHA)
The Hague
The Netherlands

communications@harmony-alliance.eu
+31 70 3020099

www.harmony-alliance.eu
www.bigdataforbloodcancer.eu

The HARMONY Alliance (HARMONY and HARMONY PLUS) is a European public-private Partnership for Big Data in Hematology. HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).